392 related articles for article (PubMed ID: 29361332)
1. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.
Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R
J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
Zieglmayer P; Focke-Tejkl M; Schmutz R; Lemell P; Zieglmayer R; Weber M; Kiss R; Blatt K; Valent P; Stolz F; Huber H; Neubauer A; Knoll A; Horak F; Henning R; Valenta R
EBioMedicine; 2016 Sep; 11():43-57. PubMed ID: 27650868
[TBL] [Abstract][Full Text] [Related]
3. Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG
Eckl-Dorna J; Weber M; Stanek V; Linhart B; Ristl R; Waltl EE; Villazala-Merino S; Hummel A; Focke-Tejkl M; Froeschel R; Neubauer A; Henning R; Perkmann T; Valenta R; Niederberger V
EBioMedicine; 2019 Dec; 50():421-432. PubMed ID: 31786130
[TBL] [Abstract][Full Text] [Related]
4. Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32.
Tulaeva I; Cornelius C; Zieglmayer P; Zieglmayer R; Schmutz R; Lemell P; Weber M; Focke-Tejkl M; Karaulov A; Henning R; Valenta R
EBioMedicine; 2020 Sep; 59():102953. PubMed ID: 32855110
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
Focke-Tejkl M; Weber M; Niespodziana K; Neubauer A; Huber H; Henning R; Stegfellner G; Maderegger B; Hauer M; Stolz F; Niederberger V; Marth K; Eckl-Dorna J; Weiss R; Thalhamer J; Blatt K; Valent P; Valenta R
J Allergy Clin Immunol; 2015 May; 135(5):1207-7.e1-11. PubMed ID: 25441634
[TBL] [Abstract][Full Text] [Related]
6. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
7. Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis.
Ellis AK; Frankish CW; O'Hehir RE; Armstrong K; Steacy L; Larché M; Hafner RP
J Allergy Clin Immunol; 2017 Aug; 140(2):486-496. PubMed ID: 28236469
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
[TBL] [Abstract][Full Text] [Related]
9. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
10. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection.
Cornelius C; Schöneweis K; Georgi F; Weber M; Niederberger V; Zieglmayer P; Niespodziana K; Trauner M; Hofer H; Urban S; Valenta R
EBioMedicine; 2016 Sep; 11():58-67. PubMed ID: 27568223
[TBL] [Abstract][Full Text] [Related]
12. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial.
Skaarup SH; Schmid JM; Skjold T; Graumann O; Hoffmann HJ
J Allergy Clin Immunol; 2021 Mar; 147(3):1011-1019. PubMed ID: 32679209
[TBL] [Abstract][Full Text] [Related]
13. Intradermal grass pollen immunotherapy increases T
Slovick A; Douiri A; Muir R; Guerra A; Tsioulos K; Hay E; Lam EPS; Kelly J; Peacock JL; Ying S; Shamji MH; Cousins DJ; Durham SR; Till SJ
J Allergy Clin Immunol; 2017 Jun; 139(6):1830-1839.e13. PubMed ID: 27773851
[TBL] [Abstract][Full Text] [Related]
14. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
15. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial.
Mösges R; Bachert C; Panzner P; Calderon MA; Haazen L; Pirotton S; Wathelet N; Durham SR; Bonny MA; Legon T; von Frenckell R; Pfaar O; Shamji MH
Allergy; 2018 Sep; 73(9):1842-1850. PubMed ID: 29512827
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
[TBL] [Abstract][Full Text] [Related]
18. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Dahl R; Stender A; Rak S
Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
[TBL] [Abstract][Full Text] [Related]
19. Persistence of the clinical effect of grass allergen peptide immunotherapy after the second and third grass pollen seasons.
Ellis AK; Frankish CW; Armstrong K; Steacy L; Tenn MW; Pawsey S; Hafner RP
J Allergy Clin Immunol; 2020 Feb; 145(2):610-618.e9. PubMed ID: 31568796
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines.
Weber M; Niespodziana K; Linhart B; Neubauer A; Huber H; Henning R; Valenta R; Focke-Tejkl M
J Allergy Clin Immunol; 2017 Nov; 140(5):1433-1436.e6. PubMed ID: 28576673
[No Abstract] [Full Text] [Related]
[Next] [New Search]
